603077.SHG Sichuan Hebang Biotechnology Co Ltd
- Market cap
- CNY 18.5B
- P/E
- -
- P/B
- 0.92x
- ROE
- 3.1%
- Dividend yield
- 0.74%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603077.SHG undervalued?
Graham numberThe Graham number of Sichuan Hebang Biotechnology Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sichuan Hebang Biotechnology Co Ltd fundamental analysis
No fundamental analysis for Sichuan Hebang Biotechnology Co Ltd yet.
Sichuan Hebang Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sichuan Hebang Biotechnology Co Ltd
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company provides original glass and smart glass, special glass, low-e coated glass, ultra-high efficiency silicon wafers, and photovoltaic packaging materials and products, as well as photovo…
Full company profileSichuan Hebang Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sichuan Hebang Biotechnology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.46B | 4.74B | 6.01B | 5.97B | 5.26B | 9.99B | 13.0B | 8.82B | 8.55B | 7.19B | 6.03B |
| Gross Profit | 835M | 1.14B | 1.24B | 1.22B | 916M | 4.11B | 5.55B | 2.00B | 537M | 828M | 1.47B |
| Operating Income | 347M | 596M | 414M | 583M | 440M | 3.59B | 4.48B | 1.54B | -61.8M | 266M | 897M |
| EBITDA | 812M | 1.14B | 1.18B | 1.28B | 1.17B | 4.28B | 5.40B | 2.41B | 924M | 507M | 828M |
| Net Income | 318M | 518M | 363M | 517M | 40.9M | 3.02B | 3.81B | 1.28B | 31.5M | -536M | 605M |
| EPS | 0.04 | 0.06 | 0.04 | 0.06 | 0.00 | 0.36 | 0.44 | 0.15 | 0.00 | -0.06 | 0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 12.9B | 13.1B | 13.3B | 14.5B | 14.7B | 17.9B | 24.1B | 24.5B | 29.6B | 28.2B | 30.4B |
| Total Liabilities | 2.15B | 1.83B | 2.09B | 3.03B | 3.43B | 3.29B | 4.34B | 4.32B | 10.6B | 10.3B | 10.7B |
| Shareholders' Equity | 10.5B | 11.0B | 11.0B | 11.2B | 11.1B | 14.2B | 19.1B | 19.6B | 18.6B | 17.9B | 19.6B |
| Cash & Short-term Investments | 309M | 831M | 1.34B | 797M | 846M | 1.77B | 4.59B | 3.06B | 7.00B | 6.70B | 7.48B |
| Total Debt | 1.24B | 916M | 1.16B | 1.86B | 2.15B | 1.37B | 1.82B | 1.62B | 7.30B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 575M | 177M | 944M | 163M | 369M | 3.20B | 2.64B | 201M | 468M | 1.08B | - |
| Capital Expenditure | 677M | 509M | 364M | 663M | 197M | 1.74B | 936M | 829M | 1.12B | 1.26B | 1.46B |
| Free Cash Flow | -102M | -332M | 581M | -500M | 172M | 1.46B | 1.71B | -748M | -648M | -183M | -947M |
| Ratios | |||||||||||
| ROE | 3.0% | 4.7% | 3.3% | 4.6% | 0.4% | 21.2% | 19.9% | 6.6% | 0.2% | -3.0% | 3.1% |
| ROA | 2.5% | 3.9% | 2.7% | 3.6% | 0.3% | 16.8% | 15.8% | 5.2% | 0.1% | -1.9% | 2.0% |
| Net Profit Margin | 9.2% | 10.9% | 6.0% | 8.7% | 0.8% | 30.2% | 29.2% | 14.5% | 0.4% | -7.5% | 10.0% |
| Debt to Equity | 0.12x | 0.08x | 0.11x | 0.17x | 0.19x | 0.10x | 0.10x | 0.08x | 0.39x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sichuan Hebang Biotechnology Co Ltd dividends
- Dividend yield
- 0.74%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Oct 15, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 136M | 0.02 | - |
| 2024 | CNY 247M | 0.03 | 783.9% |
| 2023 | CNY 393M | 0.05 | 30.6% |
| 2022 | CNY 131M | 0.02 | 3.4% |
| 2021 | CNY 78.0M | 0.01 | 2.6% |
| 2020 | CNY 92.7M | 0.01 | 226.5% |
| 2019 | CNY 71.1M | 0.01 | 13.8% |
| 2018 | CNY 253M | 0.03 | 69.7% |
| 2017 | CNY 110M | 0.01 | 21.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 22:10 on Jul 5, 2017.
Who owns Sichuan Hebang Biotechnology Co Ltd
- Insiders 38.44%
- Institutions 2.15%
- Public & others 59.42%
- Shares outstanding 8.83B
- Free float 5.59B
Sichuan Hebang Biotechnology Co Ltd company profile
- Company name
- Sichuan Hebang Biotechnology Co Ltd
- Ticker
- 603077.SHG
- ISIN
- CNE100001JM9
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jul 31, 2012
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 5,085
- Fiscal year end
- December
- Address
- Mianba Village, Leshan, China
- Phone
- 86 28 6205 0230
- Website
- hebang.cn
About Sichuan Hebang Biotechnology Co Ltd
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company provides original glass and smart glass, special glass, low-e coated glass, ultra-high efficiency silicon wafers, and photovoltaic packaging materials and products, as well as photovoltaic glass and module products. In addition, it engages in the supply of oil and gas. The company was formerly known as SichuanHebang Biotechnology Co.,Ltd. and changed its name to Sichuan Hebang Biotechnology Corporation Limited in April 2021. The company was founded in 2002 and is based in Leshan, China.
Sichuan Hebang Biotechnology Co Ltd management
3- Mr. Jun WangCFO, Accounting Supervisor & Director · born 1973
- Ms. Siying JiangSecretary to the Board · born 1987
- Wen LvGeneral Manager